Global Non-interventional Heart Failure Disease Registry (REPORT-HF)

November 13, 2018 updated by: Novartis Pharmaceuticals

International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

Study Overview

Status

Terminated

Conditions

Acute Heart Failure

Study Type

Observational

Enrollment (Actual)

18805

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Algeria
- - Algiers, Algeria, 16000
    - Novartis Investigative Site
  - Algiers, Algeria, 16040
    - Novartis Investigative Site
  - Algiers, Algeria, 16206
    - Novartis Investigative Site
  - Oran, Algeria, 31000
    - Novartis Investigative Site
Argentina
- - Buenos Aires, Argentina
    - Novartis Investigative Site
  - Buenos Aires, Argentina, C1094AAD
    - Novartis Investigative Site
  - Buenos Aires, Argentina, C1426EOB
    - Novartis Investigative Site
  - Cordoba, Argentina, X5000JHQ
    - Novartis Investigative Site
  - Cordoba, Argentina, X5000
    - Novartis Investigative Site
  - Corrientes, Argentina, W3400AFT
    - Novartis Investigative Site
  - Mendoza, Argentina, M5500AAJ
    - Novartis Investigative Site
  - Salta, Argentina, 4000
    - Novartis Investigative Site
- Buenos Aires
  - Caba, Buenos Aires, Argentina, C1181ACH
    - Novartis Investigative Site
  - Caba, Buenos Aires, Argentina, C1210AAP
    - Novartis Investigative Site
- Chaco
  - Resistencia, Chaco, Argentina, H3500CDM
    - Novartis Investigative Site
- Ciudad De Buenos Aires
  - Buenos Aires, Ciudad De Buenos Aires, Argentina, 1118
    - Novartis Investigative Site
  - Coronel Suarez, Ciudad De Buenos Aires, Argentina, 7540
    - Novartis Investigative Site
- Santa Fe
  - Rosario, Santa Fe, Argentina, S2000DSV
    - Novartis Investigative Site
  - Rosario, Santa Fe, Argentina, 2000
    - Novartis Investigative Site
Australia
- - Bedford Park, Australia, SA 5042
    - Novartis Investigative Site
- New South Wales
  - Gosford, New South Wales, Australia, 2250
    - Novartis Investigative Site
- Queensland
  - Auchenflower, Queensland, Australia, 4066
    - Novartis Investigative Site
  - Greenslopes, Queensland, Australia, 4120
    - Novartis Investigative Site
Austria
- - Eisenstadt, Austria, 7000
    - Novartis Investigative Site
  - Linz, Austria, 4021
    - Novartis Investigative Site
  - Moedling, Austria, A-2340
    - Novartis Investigative Site
  - Vienna, Austria, A-1220
    - Novartis Investigative Site
  - Wien, Austria, A-1160
    - Novartis Investigative Site
Brazil
- - Curitiba, Brazil
    - Novartis Investigative Site
  - Recife, Brazil
    - Novartis Investigative Site
  - Rio De Janeiro, Brazil
    - Novartis Investigative Site
  - Sao Jose Do Rico Preto, Brazil
    - Novartis Investigative Site
- CE
  - Fortaleza, CE, Brazil, 60864-190
    - Novartis Investigative Site
- MG
  - Belo Horizonte, MG, Brazil, 30130-100
    - Novartis Investigative Site
- PR
  - Curitiba, PR, Brazil, 80010-030
    - Novartis Investigative Site
- RJ
  - Rio de Janeiro, RJ, Brazil, 22280-020
    - Novartis Investigative Site
- SP
  - Campinas, SP, Brazil, 13060-904
    - Novartis Investigative Site
  - Tatuí, SP, Brazil, 18270-170
    - Novartis Investigative Site
Bulgaria
- - Pleven, Bulgaria, 5800
    - Novartis Investigative Site
  - Plovdiv, Bulgaria, 4002
    - Novartis Investigative Site
  - Sofia, Bulgaria, 1527
    - Novartis Investigative Site
  - Sofia, Bulgaria, 1202
    - Novartis Investigative Site
  - Sofia, Bulgaria, 1606
    - Novartis Investigative Site
  - Varna, Bulgaria, 9010
    - Novartis Investigative Site
Canada
- Alberta
  - Edmonton, Alberta, Canada, T6G 2B7
    - Novartis Investigative Site
- British Columbia
  - Vancouver, British Columbia, Canada, V6Z 1Y6
    - Novartis Investigative Site
- Nova Scotia
  - Halifax, Nova Scotia, Canada, B3H 3A7
    - Novartis Investigative Site
- Ontario
  - Ottawa, Ontario, Canada, K1Y 4W7
    - Novartis Investigative Site
- Quebec
  - Sainte-Foy, Quebec, Canada, G1V 4G5
    - Novartis Investigative Site
Chile
- - Concepcion, Chile
    - Novartis Investigative Site
  - Santiago, Chile
    - Novartis Investigative Site
  - Santiago, Chile, PISO 1
    - Novartis Investigative Site
- Santiago
  - San Miguel, Santiago, Chile, 8900000
    - Novartis Investigative Site
China
- - Beijing, China, 100053
    - Novartis Investigative Site
  - Beijing, China, 100029
    - Novartis Investigative Site
  - Beijing, China, 100034
    - Novartis Investigative Site
  - Beijing, China
    - Novartis Investigative Site
  - Beijing, China, 100022
    - Novartis Investigative Site
  - Guang Zhou, China, 510260
    - Novartis Investigative Site
  - Hangzhou, China, 310006
    - Novartis Investigative Site
  - Jinan, China, 250012
    - Novartis Investigative Site
  - Luoyang, China, 471000
    - Novartis Investigative Site
  - Shanghai, China, 200080
    - Novartis Investigative Site
  - Taiyuan, China
    - Novartis Investigative Site
  - Urumqi, China, 830000
    - Novartis Investigative Site
  - Urumqi, China, 830054
    - Novartis Investigative Site
  - Wuhan, China, 430022
    - Novartis Investigative Site
  - Xiamen, China, 361004
    - Novartis Investigative Site
  - Yangzhou, China, 225001
    - Novartis Investigative Site
  - Zhengzhou, China
    - Novartis Investigative Site
  - Zhengzhou, China, 450003
    - Novartis Investigative Site
- Beijing
  - Beijing, Beijing, China, 100044
    - Novartis Investigative Site
  - Beijing, Beijing, China, 100191
    - Novartis Investigative Site
- Fujian
  - Fuzhou, Fujian, China
    - Novartis Investigative Site
- Guangdong
  - Guangzhou, Guangdong, China, 510080
    - Novartis Investigative Site
- Hebei
  - Shijiazhuang, Hebei, China, 050000
    - Novartis Investigative Site
- Hubei
  - Wuhan, Hubei, China, 430074
    - Novartis Investigative Site
- Hunan
  - Changsha, Hunan, China, 410011
    - Novartis Investigative Site
  - Changsha, Hunan, China, 410005
    - Novartis Investigative Site
- Inner Mongolia
  - Baotou, Inner Mongolia, China, 014040
    - Novartis Investigative Site
- Jilin
  - Changchun, Jilin, China, 130021
    - Novartis Investigative Site
- Liaoning
  - Dalian, Liaoning, China, 116011
    - Novartis Investigative Site
Colombia
- - Armenia, Colombia
    - Novartis Investigative Site
  - Bogota, Colombia
    - Novartis Investigative Site
  - Bogotá, Colombia
    - Novartis Investigative Site
  - Bogotá, Colombia, 00000
    - Novartis Investigative Site
  - Cali, Colombia
    - Novartis Investigative Site
- Antioquia
  - Medellin, Antioquia, Colombia
    - Novartis Investigative Site
  - Medellin, Antioquia, Colombia, 0050010
    - Novartis Investigative Site
- Atlantico
  - Barranquilla, Atlantico, Colombia
    - Novartis Investigative Site
- Atlántico
  - Barranquilla, Atlántico, Colombia
    - Novartis Investigative Site
- Cundinamarca
  - Bogotá, Cundinamarca, Colombia, 110111
    - Novartis Investigative Site
- Santander
  - Bucaramanga, Santander, Colombia
    - Novartis Investigative Site
Ecuador
- - Guayaquil, Ecuador
    - Novartis Investigative Site
  - Portoviejo, Ecuador
    - Novartis Investigative Site
- Guayas
  - Guayaquil, Guayas, Ecuador
    - Novartis Investigative Site
- Pichincha
  - Quito, Pichincha, Ecuador, 1701
    - Novartis Investigative Site
Egypt
- - Alexandria, Egypt, 21411
    - Novartis Investigative Site
  - Cairo, Egypt
    - Novartis Investigative Site
  - Cairo, Egypt, 11566
    - Novartis Investigative Site
  - El Menia, Upper Egypt, Egypt
    - Novartis Investigative Site
  - Suez Canal Region, Egypt, 41111
    - Novartis Investigative Site
Germany
- - Berlin, Germany, 13353
    - Novartis Investigative Site
  - Bonn, Germany, 53105
    - Novartis Investigative Site
  - Essen, Germany, 45356
    - Novartis Investigative Site
  - Freiburg, Germany, 79106
    - Novartis Investigative Site
  - Goettingen, Germany, 37075
    - Novartis Investigative Site
  - Halle, Germany, 06120
    - Novartis Investigative Site
  - Hannover, Germany, 30625
    - Novartis Investigative Site
  - Heidelberg, Germany, 69120
    - Novartis Investigative Site
  - Homburg, Germany, 66421
    - Novartis Investigative Site
  - Lubeck, Germany, 23538
    - Novartis Investigative Site
  - Ludwigshafen, Germany, 67063
    - Novartis Investigative Site
  - Nürnberg, Germany, 90471
    - Novartis Investigative Site
  - Wurzburg, Germany, 97078
    - Novartis Investigative Site
Greece
- - Athens, Greece, 11526
    - Novartis Investigative Site
  - Athens, Greece, GR 115 22
    - Novartis Investigative Site
  - Athens, Greece, 54642
    - Novartis Investigative Site
  - Glyfada, Greece, 16675
    - Novartis Investigative Site
  - Ioannina, Greece, 45100
    - Novartis Investigative Site
  - Piraeus, Greece, 18454
    - Novartis Investigative Site
  - Thessaloniki, Greece, 54642
    - Novartis Investigative Site
- GR
  - Athens, GR, Greece, 115 27
    - Novartis Investigative Site
  - Athens, GR, Greece, 115 25
    - Novartis Investigative Site
  - Athens, GR, Greece, 11527
    - Novartis Investigative Site
  - Thessaloniki, GR, Greece, 570 10
    - Novartis Investigative Site
Guatemala
- - Guatemala, Guatemala, 01011
    - Novartis Investigative Site
  - Guatemala, Guatemala
    - Novartis Investigative Site
  - Guatemala City, Guatemala, 01011
    - Novartis Investigative Site
India
- - India, India, 560040
    - Novartis Investigative Site
  - Mumbai, India, 400053
    - Novartis Investigative Site
  - New Delhi, India, 110025
    - Novartis Investigative Site
  - New Delhi, India, 110002
    - Novartis Investigative Site
- Delhi
  - New Delhi, Delhi, India, 110 060
    - Novartis Investigative Site
  - New Delhi, Delhi, India, 110070
    - Novartis Investigative Site
  - New Delhi, Delhi, India, 110017
    - Novartis Investigative Site
- Goa
  - Panaji, Goa, India, 403001
    - Novartis Investigative Site
- Gujarat
  - Ahmedabad, Gujarat, India, 380 060
    - Novartis Investigative Site
  - Vadodara, Gujarat, India, 390022
    - Novartis Investigative Site
- Haryana
  - Gurgaon, Haryana, India, 122001
    - Novartis Investigative Site
- Karnataka
  - Bangalore, Karnataka, India, 560099
    - Novartis Investigative Site
  - Bangalore, Karnataka, India, 560 069
    - Novartis Investigative Site
  - Manipal, Karnataka, India, 576104
    - Novartis Investigative Site
- Maharashtra
  - Nagpur, Maharashtra, India, 440008
    - Novartis Investigative Site
  - Pune, Maharashtra, India, 411 011
    - Novartis Investigative Site
  - Pune, Maharashtra, India, 411011
    - Novartis Investigative Site
- Punjab
  - Amritsar, Punjab, India, 143004
    - Novartis Investigative Site
  - Ludhiana, Punjab, India, 141001
    - Novartis Investigative Site
  - Ludhiana, Punjab, India, 141008
    - Novartis Investigative Site
- Tamil NADU
  - Chennai, Tamil NADU, India, 600037
    - Novartis Investigative Site
- Telangana
  - Hyderabad, Telangana, India, 500082
    - Novartis Investigative Site
  - Hyderabad, Telangana, India, 500034
    - Novartis Investigative Site
- West Bengal
  - Kolkata, West Bengal, India, 700 107
    - Novartis Investigative Site
  - Kolkata, West Bengal, India, 700099
    - Novartis Investigative Site
Indonesia
- Banten
  - Tangerang, Banten, Indonesia, 15111
    - Novartis Investigative Site
- DKI Jakarta
  - East Jakarta, DKI Jakarta, Indonesia, 13630
    - Novartis Investigative Site
  - South Jakarta, DKI Jakarta, Indonesia, 12430
    - Novartis Investigative Site
  - West Jakarta, DKI Jakarta, Indonesia, 11420
    - Novartis Investigative Site
- East Java
  - Surabaya, East Java, Indonesia, 60286
    - Novartis Investigative Site
- North Sumatera
  - Medan, North Sumatera, Indonesia, 20136
    - Novartis Investigative Site
- Sumatera Barat
  - Padang, Sumatera Barat, Indonesia, 25127
    - Novartis Investigative Site
- West Java
  - Bandung, West Java, Indonesia, 40161
    - Novartis Investigative Site
  - Bekasi, West Java, Indonesia, 17144
    - Novartis Investigative Site
Israel
- - Jerusalem, Israel, 91031
    - Novartis Investigative Site
  - Jerusalem, Israel, 91240
    - Novartis Investigative Site
  - Kfar-Saba, Israel, 4428164
    - Novartis Investigative Site
  - Nazareth, Israel, 16100
    - Novartis Investigative Site
  - Sefad, Israel, 13100
    - Novartis Investigative Site
Japan
- - Nagasaki, Japan, 850-8555
    - Novartis Investigative Site
- Fukuoka
  - Kitakyushu-city, Fukuoka, Japan, 802-8555
    - Novartis Investigative Site
- Hiroshima
  - Kure, Hiroshima, Japan, 737-0023
    - Novartis Investigative Site
- Kagawa
  - Sakaide-city, Kagawa, Japan, 762-0007
    - Novartis Investigative Site
- Okayama
  - Kita-ku, Okayama, Japan, 7000084
    - Novartis Investigative Site
- Osaka
  - Hirakata-City, Osaka, Japan, 573-0153
    - Novartis Investigative Site
- Tokyo
  - Chiyoda-ku, Tokyo, Japan, 101-8643
    - Novartis Investigative Site
Jordan
- - Amman, Jordan, 11196
    - Novartis Investigative Site
  - Amman, Jordan, 11942
    - Novartis Investigative Site
  - Amman, Jordan
    - Novartis Investigative Site
  - Amman, Jordan, 11121
    - Novartis Investigative Site
  - Irbid, Jordan, 22110
    - Novartis Investigative Site
Korea, Republic of
- - Busan, Korea, Republic of, 612-896
    - Novartis Investigative Site
  - Incheon, Korea, Republic of, 403-720
    - Novartis Investigative Site
  - Pusan, Korea, Republic of, 614-735
    - Novartis Investigative Site
  - Seoul, Korea, Republic of, 136-705
    - Novartis Investigative Site
  - Seoul, Korea, Republic of, 07061
    - Novartis Investigative Site
  - Suwon, Korea, Republic of, 16247
    - Novartis Investigative Site
  - Taegu, Korea, Republic of, 700 -721
    - Novartis Investigative Site
- Bucheon-si
  - Gyeonggi-do, Bucheon-si, Korea, Republic of, 422-711
    - Novartis Investigative Site
- Chungcheongbuk-do
  - Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 28644
    - Novartis Investigative Site
- Gangwon-Do
  - Wonju, Gangwon-Do, Korea, Republic of, 220-701
    - Novartis Investigative Site
- Korea
  - Daejeon, Korea, Korea, Republic of, 301-721
    - Novartis Investigative Site
Lebanon
- - Beirut, Lebanon, 1107 2020
    - Novartis Investigative Site
  - Beirut, Lebanon, 6301
    - Novartis Investigative Site
  - Beirut, Lebanon
    - Novartis Investigative Site
  - Jbeil, Lebanon
    - Novartis Investigative Site
  - Saida, Lebanon, 652
    - Novartis Investigative Site
- LBN
  - El Chouf, LBN, Lebanon
    - Novartis Investigative Site
Malaysia
- - Johor Bahru, Malaysia, 80100
    - Novartis Investigative Site
  - Kuala Lumpur, Malaysia, 50586
    - Novartis Investigative Site
- Kedah
  - Alor Setar, Kedah, Malaysia, 05460
    - Novartis Investigative Site
- Kelantan
  - Kota Bahru, Kelantan, Malaysia, 16150
    - Novartis Investigative Site
- Penang
  - Pulau Pinang, Penang, Malaysia, 10990
    - Novartis Investigative Site
Mexico
- - Aguascalientes, Mexico, 20230
    - Novartis Investigative Site
  - San Luis Potosi, Mexico, 78240
    - Novartis Investigative Site
  - San Luis Potosi, Mexico, 78213
    - Novartis Investigative Site
  - Xalapa, Mexico, 91020
    - Novartis Investigative Site
  - Xalapa, Mexico, 91193
    - Novartis Investigative Site
- Distrito Federal
  - Mexico, Distrito Federal, Mexico, 14080
    - Novartis Investigative Site
  - Mexico, Distrito Federal, Mexico, 03100
    - Novartis Investigative Site
  - Mexico, Distrito Federal, Mexico, 06090
    - Novartis Investigative Site
- Sinaloa SN
  - Culiacán, Sinaloa SN, Mexico, 80230
    - Novartis Investigative Site
Morocco
- - Casablanca, Morocco
    - Novartis Investigative Site
  - Marrakech, Morocco, 40 000
    - Novartis Investigative Site
  - Rabat, Morocco, 10 000
    - Novartis Investigative Site
Netherlands
- - Amsterdam, Netherlands, 1034CS
    - Novartis Investigative Site
  - Groningen, Netherlands, 9713 GZ
    - Novartis Investigative Site
  - Leiderdorp, Netherlands, NL-2353 GA
    - Novartis Investigative Site
  - Sneek, Netherlands, 8601ZK
    - Novartis Investigative Site
  - Venlo, Netherlands, 5912 BL
    - Novartis Investigative Site
  - Zwolle, Netherlands, 8025 AB
    - Novartis Investigative Site
Norway
- - Hønefoss, Norway, 3501
    - Novartis Investigative Site
  - Oslo, Norway, 370
    - Novartis Investigative Site
  - Skien, Norway, NO-3710
    - Novartis Investigative Site
Panama
- - Panama, Panama
    - Novartis Investigative Site
  - Panama City, Panama
    - Novartis Investigative Site
- Panamá
  - San Jose De David, Panamá, Panama
    - Novartis Investigative Site
Philippines
- Baguio
  - Baguio City, Baguio, Philippines, 2600
    - Novartis Investigative Site
- Cagayan
  - Cagayan De Oro City, Cagayan, Philippines, 9000
    - Novartis Investigative Site
- Cebu
  - Cebu City, Cebu, Philippines, 6000
    - Novartis Investigative Site
- Davao
  - Davao City, Davao, Philippines, 8000
    - Novartis Investigative Site
- Manila
  - Quezon City, Manila, Philippines, 1100
    - Novartis Investigative Site
- Metro Manila
  - Manila, Metro Manila, Philippines, 1000
    - Novartis Investigative Site
- Pampanga
  - Angeles City, Pampanga, Philippines, 2009
    - Novartis Investigative Site
Romania
- - Bucharest, Romania, 022322
    - Novartis Investigative Site
  - Bucharest, Romania, 030 171
    - Novartis Investigative Site
  - Buzau, Romania, 120140
    - Novartis Investigative Site
  - Cluj-Napoca, Romania, 400006
    - Novartis Investigative Site
  - Focsani, Romania, 620034
    - Novartis Investigative Site
  - Lasi, Romania, 700075
    - Novartis Investigative Site
  - Timisoara, Romania, 300054
    - Novartis Investigative Site
- Napoca
  - Cluj, Napoca, Romania, 400006
    - Novartis Investigative Site
Russian Federation
- - Kazan, Russian Federation, 420033
    - Novartis Investigative Site
  - Kemerovo, Russian Federation, 654005
    - Novartis Investigative Site
  - Krasnodar, Russian Federation, 350086
    - Novartis Investigative Site
  - Moscow, Russian Federation, 127473
    - Novartis Investigative Site
  - Moscow, Russian Federation, 117292
    - Novartis Investigative Site
  - Novosibirsk, Russian Federation, 630091
    - Novartis Investigative Site
  - Ryazan, Russian Federation, 390026
    - Novartis Investigative Site
  - S-Petersburg, Russian Federation, 194354
    - Novartis Investigative Site
  - Saint Petersburg, Russian Federation, 197341
    - Novartis Investigative Site
  - Saratov, Russian Federation, 410004
    - Novartis Investigative Site
  - Saratov, Russian Federation, 410017
    - Novartis Investigative Site
  - St. Petersburg, Russian Federation, 191015
    - Novartis Investigative Site
  - St.-Petersburg, Russian Federation, 194044
    - Novartis Investigative Site
  - Stavropol, Russian Federation, 355030
    - Novartis Investigative Site
  - Tyumen, Russian Federation, 625023
    - Novartis Investigative Site
  - Ulyanovsk, Russian Federation, 432057
    - Novartis Investigative Site
  - Vladivostok, Russian Federation, 690002
    - Novartis Investigative Site
  - Volgograd, Russian Federation, 400026
    - Novartis Investigative Site
Saudi Arabia
- - Al Ahsa, Saudi Arabia
    - Novartis Investigative Site
  - Dammam, Saudi Arabia, 31463
    - Novartis Investigative Site
  - Dammam, Saudi Arabia, 15215
    - Novartis Investigative Site
  - Khamis Mushayt, Saudi Arabia, 62413
    - Novartis Investigative Site
  - Riyadh, Saudi Arabia, 3643
    - Novartis Investigative Site
South Africa
- - Bloemfontein, South Africa, 9301
    - Novartis Investigative Site
  - Cape Town, South Africa, 7505
    - Novartis Investigative Site
  - Cape Town, South Africa, 7405
    - Novartis Investigative Site
  - Rivonia, South Africa, 2128
    - Novartis Investigative Site
- Kwa-Zulu Natal
  - Durban, Kwa-Zulu Natal, South Africa, 4052
    - Novartis Investigative Site
Spain
- - Barcelona, Spain, 08041
    - Novartis Investigative Site
  - Cordoba, Spain
    - Novartis Investigative Site
  - Leon, Spain, 24080
    - Novartis Investigative Site
  - Murcia, Spain, 30008
    - Novartis Investigative Site
- Catalunya
  - Barcelona, Catalunya, Spain, 08035
    - Novartis Investigative Site
  - Tarragona, Catalunya, Spain, 43005
    - Novartis Investigative Site
- Cataluña
  - Barcelona, Cataluña, Spain, 08036
    - Novartis Investigative Site
- Comunidad Valenciana
  - Alicante, Comunidad Valenciana, Spain, 03010
    - Novartis Investigative Site
- Extremadura
  - Merida, Extremadura, Spain, 06800
    - Novartis Investigative Site
- Islas Baleares
  - Mallorca, Islas Baleares, Spain, 07198
    - Novartis Investigative Site
- Las Palmas De G.C
  - Las Palmas de Gran Canaria, Las Palmas De G.C, Spain, 35020
    - Novartis Investigative Site
- Madrid
  - Majadahonda, Madrid, Spain, 28222
    - Novartis Investigative Site
- Pais Vasco
  - Barakaldo, Pais Vasco, Spain, 48903
    - Novartis Investigative Site
Sweden
- - Göteborg, Sweden, 416 85
    - Novartis Investigative Site
  - Helsingborg, Sweden, 252 20
    - Novartis Investigative Site
  - Karlshamn, Sweden, 37480
    - Novartis Investigative Site
  - Linkoping, Sweden, 581 85
    - Novartis Investigative Site
  - Malmö, Sweden, 205 20
    - Novartis Investigative Site
  - Trollhättan, Sweden, 46173
    - Novartis Investigative Site
Switzerland
- - Basel, Switzerland, 4031
    - Novartis Investigative Site
  - Bruderholz, Switzerland, 4101
    - Novartis Investigative Site
  - Zuerich, Switzerland, 8032
    - Novartis Investigative Site
Taiwan
- - Lin-Kou, Taiwan, 33305
    - Novartis Investigative Site
  - Taichung, Taiwan, 40705
    - Novartis Investigative Site
  - Tainan, Taiwan, 70421
    - Novartis Investigative Site
  - Taipei, Taiwan, 10002
    - Novartis Investigative Site
  - Taipei, Taiwan, 11217
    - Novartis Investigative Site
  - Taipei, Taiwan, 110
    - Novartis Investigative Site
Thailand
- - Bangkok, Thailand, 10400
    - Novartis Investigative Site
  - Bangkok, Thailand, 10310
    - Novartis Investigative Site
  - Chiang Mai, Thailand, 50200
    - Novartis Investigative Site
  - Muang, Thailand, 65000
    - Novartis Investigative Site
  - Muang, Thailand, 12120
    - Novartis Investigative Site
  - Muang, Thailand, 30000
    - Novartis Investigative Site
- THA
  - Khon Kaen, THA, Thailand, 40002
    - Novartis Investigative Site
Tunisia
- - Monastir, Tunisia, 5000
    - Novartis Investigative Site
  - Sousse, Tunisia, 4011
    - Novartis Investigative Site
  - Tunis, Tunisia, 1007
    - Novartis Investigative Site
  - Tunis, Tunisia, 1008
    - Novartis Investigative Site
  - Tunis, Tunisia, 1006
    - Novartis Investigative Site
Turkey
- - Ankara, Turkey, 06100
    - Novartis Investigative Site
  - Ankara, Turkey, 06590
    - Novartis Investigative Site
  - Bursa, Turkey
    - Novartis Investigative Site
  - Bursa, Turkey, 16059
    - Novartis Investigative Site
  - Diskapi / Ankara, Turkey, 06110
    - Novartis Investigative Site
  - Haydarpasa/Istanbul, Turkey, 34668
    - Novartis Investigative Site
  - Istanbul, Turkey, 34093
    - Novartis Investigative Site
  - Meselik / Eskisehir, Turkey, 26480
    - Novartis Investigative Site
  - Pendik / Istanbul, Turkey, 34899
    - Novartis Investigative Site
  - Sivas, Turkey, 58140
    - Novartis Investigative Site
United Arab Emirates
- - Abu Dhabi, United Arab Emirates, 51900
    - Novartis Investigative Site
  - Al Ain, United Arab Emirates
    - Novartis Investigative Site
  - Dubai, United Arab Emirates
    - Novartis Investigative Site
  - Dubai, United Arab Emirates, 7272
    - Novartis Investigative Site
United Kingdom
- - Chesterfield, United Kingdom, BS1 3NU
    - Novartis Investigative Site
  - Telford, United Kingdom, TF1 6TF
    - Novartis Investigative Site
  - Uxbridge, United Kingdom, UB8 3NN
    - Novartis Investigative Site
  - Wakefield, United Kingdom, WF1 4DG
    - Novartis Investigative Site
  - York, United Kingdom, YO31 8HE
    - Novartis Investigative Site
- Birmingham
  - Edgbaston, Birmingham, United Kingdom, B15 2WB
    - Novartis Investigative Site
- Cleveland
  - Stockton on Tees, Cleveland, United Kingdom, TS19 8PE
    - Novartis Investigative Site
- West Yorkshire
  - Bradford, West Yorkshire, United Kingdom, BD9 6RJ
    - Novartis Investigative Site
- Yorkshire
  - Chesterfield, Yorkshire, United Kingdom, S44 5BL
    - Novartis Investigative Site
  - Herts, Yorkshire, United Kingdom, SG1 4AB
    - Novartis Investigative Site
United States
- California
  - San Diego, California, United States, 92103
    - Novartis Investigative Site
  - San Francisco, California, United States, 94143-0780
    - Novartis Investigative Site
- Illinois
  - Chicago, Illinois, United States, 60611
    - Novartis Investigative Site
- Indiana
  - Indianapolis, Indiana, United States, 46202
    - Novartis Investigative Site
- Kansas
  - Kansas City, Kansas, United States, 66160
    - Novartis Investigative Site
- Louisiana
  - New Orleans, Louisiana, United States, 70112
    - Novartis Investigative Site
  - New Orleans, Louisiana, United States, 70121
    - Novartis Investigative Site
- Michigan
  - Detroit, Michigan, United States, 48202
    - Novartis Investigative Site
  - Detroit, Michigan, United States, 48201
    - Novartis Investigative Site
- Mississippi
  - Jackson, Mississippi, United States, 39216
    - Novartis Investigative Site
- New York
  - New York, New York, United States, 10029
    - Novartis Investigative Site
  - Stony Brook, New York, United States, 11794
    - Novartis Investigative Site
- Ohio
  - Cincinnati, Ohio, United States, 45267
    - Novartis Investigative Site
- Tennessee
  - Nashville, Tennessee, United States, 37203
    - Novartis Investigative Site
- Texas
  - Dallas, Texas, United States, 75390
    - Novartis Investigative Site
Vietnam
- - Ho Chi Minh, Vietnam
    - Novartis Investigative Site
  - Ho Chi Minh City, Vietnam
    - Novartis Investigative Site
  - Ho Chi Minh City, Vietnam, District 7
    - Novartis Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Enrollment of adult patients hospitalized with a primary diagnosis of acute Heart Failure (HF), i.e. new-onset (first diagnosis) HF or decompensation of chronic HF

Description

Inclusion Criteria:

Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure.

Exclusion Criteria:

1-Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor).

2. Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients with different characteristics of heart faliure (HF) at hospitalization Time Frame: From admission to discharge of the patient's index hospitalization (minimum 24 hours)	From admission to discharge of the patient's index hospitalization (minimum 24 hours)
Percentage of patients who die during the index hospitalization Time Frame: From admission to discharge of the patient's index hospitalization (minimum 24 hours)	From admission to discharge of the patient's index hospitalization (minimum 24 hours)
Percentage of patients who die during the follow-up period post-discharge Time Frame: up to 3 years	up to 3 years
Percentage of patients who are re-hospitalized by primary re-hospitalization reason (Cardiovascular and non-Cardiovascular) Time Frame: up to 3 years	up to 3 years
Number of patients with different characteristics of post-discharge patient management Time Frame: up to 3 years	up to 3 years
Healthcare Resource Utilization assessed by number of patients with re-hospitalizations Time Frame: up to 3 years	up to 3 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Health-related Quality of life (HRQoL) based on patient reported data as measured by EQ-5D and the Kansas City Cardiomyopathy Questionnaire (KCCQ) questionnaires Time Frame: up to 3 years	up to 3 years
Caregiver burden based on Caregiver Burden Questionnaire -Heart Failure (CBQ-HF) and Work Productivity and Activity Impairment (WPAI) questionnaires Time Frame: up to 3 years	up to 3 years
Correlation ratio between practice patterns and outcomes Time Frame: up to 3 years	up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novartis Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, Angermann CE, Ertl G, Dahlstrom U, Hu D, Dickstein K, Perrone SV, Ghadanfar M, Bermann G, Noe A, Schweizer A, Maier T, Gheorghiade M. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May;17(5):527-33. doi: 10.1002/ejhf.262. Epub 2015 Mar 10.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 23, 2014

Primary Completion (Actual)

March 31, 2018

Study Completion (Actual)

March 31, 2018

Study Registration Dates

First Submitted

October 13, 2015

First Submitted That Met QC Criteria

November 2, 2015

First Posted (Estimate)

November 3, 2015

Study Record Updates

Last Update Posted (Actual)

November 14, 2018

Last Update Submitted That Met QC Criteria

November 13, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

CRPORTHF

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Heart Failure

Lakeland Regional Health Systems, Inc.

Recruiting

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure (US-DASH)

Heart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IV

United States
Idorsia Pharmaceuticals Ltd.

Completed

Tezosentan in Acute Heart Failure (VERITAS 1)

Acute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart Failure

United States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Tezosentan in the Treatment of Acute Heart Failure (VERITAS 2)

Acute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart Failure

United States, Hungary, Australia, Czechia, Germany, Italy, Norway, United Kingdom
Abiomed Inc.

Completed

SVC Occlusion in Subjects With Acute Decompensated Heart Failure (VENUS-HF)

Heart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart Failure

United States
Maastricht University Medical Center
Charite University, Berlin, Germany; Erasmus Medical Center; University College... and other collaborators

Not yet recruiting

Therapy Adjustment and IndividuaLized Response With Biomarker Observation in ReaL-world Heart Failure (TAILOR-HF)

Chronic Heart Failure | Acute Decompensated Heart Failure
Maastricht University Medical Center
University Medical Center Groningen; Maastricht University

Withdrawn

PREcision meDICine in Treatment in CardioVascular Disease (PREDICT-CVD)

Chronic Heart Failure | Acute Decompensated Heart Failure

Netherlands
University of Health Sciences Lahore

Recruiting

Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure

Acute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, Systolic

Pakistan
Hospital General de Agudos "Dr. Cosme Argerich"
Hospital General de Agudos "Dr. Cosme Argerich"

Recruiting

Digoxin After Acute Heart Failure (DIG-DICA) (DIG-DICA)

Acute Heart Failure (AHF)

Argentina
Jin Joo Park

Recruiting

Acute Heart Failure Registry (B-AHF)

Acute Heart Failure (AHF)

South Korea
University Medical Center Ho Chi Minh City (UMC)
University of Medicine and Pharmacy at Ho Chi Minh City; INSERM UMR-942, Paris... and other collaborators

Recruiting

Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction (VN-RAPID)

Acute Heart Failure (AHF) | Acute Heart Failure With Reduced Ejection Fraction

Vietnam

Global Non-interventional Heart Failure Disease Registry (REPORT-HF)

International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure

Study Overview

Status

Conditions

Study Type

Enrollment (Actual)

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Sampling Method

Study Population

Description

Study Plan

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Time Frame

Secondary Outcome Measures

Outcome Measure

Time Frame

Collaborators and Investigators

Sponsor

Publications and helpful links

General Publications

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Acute Heart Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations